NOTE PAYABLE (Details Textual) - USD ($) |
1 Months Ended | 3 Months Ended | 9 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Mar. 03, 2017 |
Feb. 24, 2017 |
Sep. 28, 2016 |
Sep. 30, 2013 |
Jun. 30, 2018 |
Jun. 30, 2017 |
Jun. 30, 2018 |
Jun. 30, 2017 |
Sep. 30, 2017 |
Feb. 20, 2017 |
|
| Note Payable [Line Items] | ||||||||||
| Interest Expense, Debt | $ 0 | $ 0 | $ 0 | $ 52,000 | ||||||
| Debt instrument, unamortized discount | 0 | 0 | $ 0 | |||||||
| Repayments of Notes Payable | 0 | 1,000,000 | ||||||||
| REGISTERED DIRECT OFFERING 2017 [Member] | ||||||||||
| Note Payable [Line Items] | ||||||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.75 | |||||||||
| Stock Issued During Period, Value, New Issues | $ 6,100,000 | |||||||||
| Loans | ||||||||||
| Note Payable [Line Items] | ||||||||||
| Notes Payable | 944,707 | 944,707 | ||||||||
| Interest Expense, Debt | 0 | $ 0 | ||||||||
| 2014 Warrant | ||||||||||
| Note Payable [Line Items] | ||||||||||
| Notes Payable | 55,293 | 55,293 | ||||||||
| Interest Expense, Debt | 0 | $ 22,100 | ||||||||
| Massachusetts Life Sciences Center | ||||||||||
| Note Payable [Line Items] | ||||||||||
| Subordinated Debt | $ 1,000,000 | $ 1,000,000 | $ 1,000,000 | |||||||
| Debt Instrument, Payment Terms | (i) interest on the MLSC Loan decreased from 10% per annum to 7% per annum beginning October 3, 2016; and (ii) the MLSC Loan became due and payable on the earlier of October 3, 2017 (“Maturity Date”), the occurrence of a Corporate Event (which was defined as the occurrence of either a Qualified Sale or Qualified Financing), or the occurrence of a Default (as defined in the promissory note issued in connection with the MLSC Loan Agreement). In addition, under the terms of the Amendment, (a) beginning October 3, 2016, the Company began amortizing the principal and accrued interest under the MLSC Loan by making the first of 13 monthly payments of approximately $106,022, with the last payment scheduled to occur on the Maturity Date; and (b) the term “Qualified Financing” was defined to mean one or more financing transactions in which we receive, in a single transaction or series of transactions, cumulative net proceeds of not less than five million dollars ($5,000,000) at any time after October 3, 2016. | The loan originally bore interest at a rate of 10% per annum, and was originally scheduled to become fully due and payable on the earlier of (i) September 30, 2018, (ii) the occurrence of an event of default under the MLSC Loan Agreement, or (iii) the completion of a sale of substantially all of our assets, a change-of-control transaction (“Qualified Sale”) or one or more financing transactions in which we receive from third parties other than our then existing shareholders net proceeds of $5,000,000 or more in a 12-month period | ||||||||
| Warrants Issued To Purchase Of Common Stock | 145,985 | |||||||||
| Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.27 | |||||||||
| Debt Instrument, Increase, Accrued Interest | $ 232,000 | |||||||||
| Debt Instrument, Interest Rate, Stated Percentage | 7.00% | |||||||||
| Repayments of Notes Payable | $ 830,000 | |||||||||
| Debt Instrument, Reduction In Interest Expenses | $ 250,000 | |||||||||